TEDA TIANJIN, China--(BUSINESS WIRE)--Asymchem Laboratories (Tianjin) Co., Ltd. (Stock Code 002821.SZ/6821.HK) announced today that it will operate the former Pfizer U.K. small molecule API pilot plant and part of the development laboratories through a new lease agreement between Asymchem and Discovery Park, establishing Asymchem’s first manufacturing footprint in Europe.

中国天津泰达——（商业新闻短讯）——阿西姆化学实验室（天津）有限公司（股票代码002821.SZ/6821.HK）今天宣布，将通过阿西姆化学与Discovery Park之间的新租赁协议，运营前辉瑞英国小分子原料药中试工厂和部分开发实验室，建立阿西姆化学在欧洲的第一个制造足迹。

Asymchem will continue to operate the site in Sandwich, Kent, as a clinical small molecule development and manufacturing facility to meet global client demands for pharma services and supply..

Asymchem将继续运营位于肯特郡Sandwich的工厂，作为临床小分子开发和制造设施，以满足全球客户对制药服务和供应的需求。。

The development laboratories are expected to begin operation in June 2024, followed by the API pilot plant in August. The site is expected to employ approximately 100 individuals by the end of 2024, including many staff previously employed by Pfizer. Planned additions for the site include capabilities for the manufacture of peptides and oligonucleotides, as well as sustainability capabilities utilizing continuous flow and biocatalysis..

开发实验室预计将于2024年6月开始运营，随后将于8月建成API中试工厂。预计到2024年底，该网站将雇用大约100名员工，其中包括许多之前受雇于辉瑞的员工。该场地的计划新增项目包括肽和寡核苷酸的生产能力，以及利用连续流动和生物催化的可持续发展能力。。

“We are excited to become a part of the European pharma manufacturing community,” said Chairman and CEO of Asymchem Group, Dr. Hao Hong. “Meeting the needs of our clients in bringing manufacturing into the Western market will continue to be part of our long-term strategy to meet overall global business demands.”.

Asymchem集团董事长兼首席执行官郝红博士表示：“我们很高兴成为欧洲制药制造界的一员。”。“满足客户将制造业带入西方市场的需求将继续是我们满足全球总体业务需求的长期战略的一部分。”。

Mayer Schreiber, CEO of Discovery Park, said: “We are delighted to welcome Asymchem to Discovery Park this summer. The organisation has selected Discovery Park as their European base and home to their first manufacturing facility in Europe, bringing new jobs and safeguarding scientific talent. Asymchem joins a burgeoning community of over 160 companies in a designated Life Sciences Opportunity Zone, representing an incredible talent pool which contributes significantly to the U.K.

Discovery Park首席执行官梅耶·施雷伯（Mayer Schreiber）表示：“我们很高兴欢迎Asymchem今年夏天来到Discovery Park。该组织已选择Discovery Park作为其欧洲基地，并在欧洲建立了第一家制造工厂，带来了新的就业机会，保护了科学人才。Asymchem加入了一个由160多家公司组成的新兴社区，位于指定的生命科学机会区，代表了一个令人难以置信的人才库，为英国做出了重大贡献。

life sciences economy.”.

生命科学经济。”。

About Asymchem

关于Asymchem

Asymchem is a global technology-driven contract development and manufacturing organization (CDMO) providing services to the pharmaceutical industry. Founded in 1997, Asymchem employs over 9300 personnel world-wide, with R&D and manufacturing operations in China and the U.S.

Asymchem是一家全球技术驱动的合同开发和制造组织（CDMO），为制药行业提供服务。Asymchem成立于1997年，在全球拥有9300多名员工，在中国和美国拥有研发和制造业务。

Forward-Looking Statements

前瞻性声明

This press release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements.

本新闻稿可能包含某些前瞻性声明，这些声明本质上具有重大风险和不确定性。“预期”、“相信”、“估计”、“预期”、“打算”等与公司相关的词语旨在识别某些此类前瞻性陈述。

The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of the Company with respect to future events at the time these statements are made.

公司不打算定期更新这些前瞻性声明。这些前瞻性陈述是基于公司管理层在做出这些陈述时对未来事件的现有信念、假设、期望、估计、预测和理解。

These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, without limitation, future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions..

这些声明并不能保证未来的发展，并受到风险、不确定性和其他因素的影响，其中一些因素超出了公司的控制范围，难以预测。因此，由于多种因素，包括但不限于我们业务的未来变化或发展、公司的竞争环境以及政治、经济、法律和社会条件，实际结果可能与前瞻性声明中包含的信息存在重大差异。。

The Company, its directors and the employees assume (a) no obligation to correct or update the forward-looking statements contained in this announcement; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

公司、董事和员工不承担（a）纠正或更新本公告中所含前瞻性声明的义务；（b）如果任何前瞻性陈述没有实现或证明不正确，则不承担任何责任。

About Discovery Park

关于Discovery Park

Discovery Park is a thriving UK life science community for visionary entrepreneurs and leaders. Within easy reach of London, Discovery Park spearheads Kent’s flourishing science and technology cluster.

探索公园是一个蓬勃发展的英国生命科学社区，面向有远见的企业家和领导者。在距离伦敦不远的地方，探索公园引领着肯特蓬勃发展的科技集群。

Discovery Park offers state-of-the-art labs, modern offices and manufacturing facilities, unrivalled flexibility and comprehensive support including access to finance and a strong local talent pool.

Discovery Park提供最先进的实验室、现代化的办公室和制造设施、无与伦比的灵活性和全面的支持，包括获得资金和强大的本地人才库。

Discovery Park has been a major centre for life science for nearly 70 years and is home to 160+ companies across a growing tenant community of dynamic start-ups through to global corporations. This includes Algaecytes, Canterbury Christ Church University, Concept Life Sciences, eXroid, Genea Biomedx, LGC, Pfizer, Psyros Diagnostics, Salvensis, Viatris, VisusNano and Wren Healthcare..

Discovery Park是生命科学的主要中心已有近70年的历史，拥有160多家公司，这些公司分布在不断增长的动态初创企业租户社区中，一直到全球公司。这包括Algaecytes，坎特伯雷基督教堂大学，概念生命科学，eXroid，Genea Biomedx，LGC，辉瑞，Psyros Diagnostics，Salvensis，Viatris，VisusNano和Wren Healthcare。。